GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Cyclically Adjusted FCF per Share

Biotest AG (Biotest AG) Cyclically Adjusted FCF per Share : $0.05 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Biotest AG's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.316. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.05 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biotest AG's average Cyclically Adjusted FCF Growth Rate was 600.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -46.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -47.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Biotest AG was -29.40% per year. The lowest was -61.10% per year. And the median was -40.35% per year.

As of today (2024-06-08), Biotest AG's current stock price is $30.48. Biotest AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.05. Biotest AG's Cyclically Adjusted Price-to-FCF of today is 609.60.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biotest AG was 4300.00. The lowest was 20.60. And the median was 62.30.


Biotest AG Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Biotest AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Cyclically Adjusted FCF per Share Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.29 0.24 0.04 0.05

Biotest AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.09 -0.06 0.05 0.05

Competitive Comparison of Biotest AG's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Biotest AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biotest AG's Cyclically Adjusted Price-to-FCF falls into.



Biotest AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biotest AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.316/125.0381*125.0381
=-0.316

Current CPI (Mar. 2024) = 125.0381.

Biotest AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.731 99.543 -0.918
201409 -0.144 99.823 -0.180
201412 0.863 99.543 1.084
201503 0.357 99.717 0.448
201506 0.522 100.417 0.650
201509 0.085 100.417 0.106
201512 0.107 99.717 0.134
201603 0.566 100.017 0.708
201606 0.835 100.717 1.037
201609 -0.074 101.017 -0.092
201612 0.506 101.217 0.625
201703 -0.337 101.417 -0.415
201706 -0.301 102.117 -0.369
201709 0.419 102.717 0.510
201712 1.302 102.617 1.586
201803 -0.973 102.917 -1.182
201806 -0.602 104.017 -0.724
201809 -0.291 104.718 -0.347
201812 0.345 104.217 0.414
201903 -0.298 104.217 -0.358
201906 -0.007 105.718 -0.008
201909 -0.681 106.018 -0.803
201912 -0.047 105.818 -0.056
202003 -0.301 105.718 -0.356
202006 -0.419 106.618 -0.491
202009 -0.411 105.818 -0.486
202012 0.625 105.518 0.741
202103 -0.481 107.518 -0.559
202106 0.084 108.486 0.097
202109 0.488 109.435 0.558
202112 0.824 110.384 0.933
202203 0.584 113.968 0.641
202206 -0.497 115.760 -0.537
202209 -0.479 118.818 -0.504
202212 -0.622 119.345 -0.652
202303 -1.038 122.402 -1.060
202306 -1.007 123.140 -1.023
202309 0.156 124.195 0.157
202312 1.827 123.773 1.846
202403 -0.316 125.038 -0.316

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Biotest AG  (OTCPK:BIESF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biotest AG's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=30.48/0.05
=609.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biotest AG was 4300.00. The lowest was 20.60. And the median was 62.30.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Biotest AG Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Biotest AG's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (Biotest AG) Business Description

Industry
Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Biotest AG (Biotest AG) Headlines

From GuruFocus

Nine Months 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Full Year 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024